Visura Technologies, a medical device company based in Minneapolis, has recently introduced the TEECAD mini, a new advancement in transesophageal echocardiography (TEE) imaging technology. Building on the success of their FDA-cleared TEECAD System, Visura aims to enhance this unique technology by working with smaller probes. This effort is specifically geared towards adult patients with anatomical needs that are not adequately met by standard TEE probe sizes.
The launch of the TEECAD mini program marks a significant milestone for Visura, following an 85% increase in evaluations at major medical centers and the growth of their clinical and commercialization teams. Dr. David Marmor, the founder and chief medical officer of Visura, emphasized the lack of substantial updates in TEE probe technology since the 1970s and underscored the critical advancement represented by TEECAD. Clinical data presented by Dr. Sunil Mankad from Mayo Clinic at last year’s ASE meeting demonstrated the safety and efficacy of TEECAD in esophageal imaging, showing reduced probe placement time and increased first-pass intubation success rates without any adverse events.
Visura’s commitment to innovation and expanding their product portfolio aligns with market demands and enhances patient care. At the upcoming American Society of Echocardiography (ASE) 2024, Visura will seek input from key opinion leaders and showcase the benefits of the TEECAD System at the TEECAD Innovation Station. By continuing to push boundaries in transesophageal echocardiography imaging technology, Visura is poised to revolutionize patient care for years to come.
To access more exclusive content, including this article, please consider subscribing. Subscribe now for more information on this topic and to stay updated on the latest industry developments.
In conclusion, Visura Technologies’ latest innovation is set to transform transesophageal echocardiography (TEE) imaging technology by introducing a smaller version of their FDA-cleared system – TEECAD mini. The company’s commitment to innovation has led them to expand their product portfolio while meeting market demands. Clinical data presented at last year’s ASE meeting demonstrated the safety and efficacy of TEECAD in esophageal imaging, paving way for further advancements in patient care.
At ASE 2024, Visura will seek input from key opinion leaders while showcasing
_w=1200_h=630.png?v=20230522122229)